apararenone

non-steroidal compound with mineralocorticoid receptor agonist activity

Also Known As:

MT-3995; N-(4-(4-Fluorophenyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)methanesulfonamide

Networked: 10 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Oxazines: 9
    - apararenone: 10
Organic Chemicals: 133
- Amides: 2428
  - Sulfonamides: 2809
    - apararenone: 10
- Sulfur Compounds: 278
  - Sulfones: 534
    - Sulfonamides: 2809
      - apararenone: 10

Experts

1.	Kolkhof, Peter: 2 articles (01/2022 - 07/2017)
2.	Hashimoto, Gaia: 2 articles (09/2021 - 02/2021)
3.	Inagaki, Masaya: 2 articles (09/2021 - 02/2021)
4.	Totsuka, Naoko: 2 articles (09/2021 - 02/2021)
5.	Akatsuka, Hidenori: 1 article (01/2022)
6.	Bakris, George L: 1 article (01/2022)
7.	Iguchi, Taku: 1 article (01/2022)
8.	Iijima, Toru: 1 article (01/2022)
9.	Ikeda, Tomoko: 1 article (01/2022)
10.	Kato, Harutoshi: 1 article (01/2022)

Related Diseases

1.	Diabetic Nephropathies (Diabetic Nephropathy) 02/01/2021 - "Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study." 02/01/2021 - "We investigated the efficacy and safety of apararenone (MT-3995), a non-steroidal compound with mineralocorticoid receptor agonist activity, in patients with stage 2 diabetic nephropathy (DN). " 01/01/2022 - "Recently, a new class of non-steroidal MRAs (including esaxerenone, AZD9977, apararenone, KBP-5074 and finerenone) have been developed with an improved benefit-risk profile and a novel indication for finerenone for diabetic kidney disease. "
2.	Fibrosis (Cirrhosis) 09/01/2021 - "In patients with NASH, apararenone 10 mg/day for 72 weeks was effective in decreasing ALT levels, improved multiple potential fibrosis markers, and was safe and well tolerated. " 09/01/2021 - "The percentage of patients with improvement of 1 point or more in fibrosis stage/without nonalcoholic fatty liver disease activity score worsening was 41.7% with apararenone and 26.1% with placebo (p = 0.203). " 09/01/2021 - "The apararenone group showed greater reductions from baseline in fibrosis markers (type IV collagen 7S and procollagen-3 N-terminal peptide) and noninvasive tests of fibrosis (enhanced liver fibrosis score and Fibrosis-4 index) at all time points versus placebo. "
3.	Hypertension (High Blood Pressure) 01/01/2021 - "Other nonsteroidal MRA such as apararenone, finerenone, AZD9977, and LY2623091 are in different clinical trials in patients with hypertension suffering from renal or hepatic fibrotic diseases. " 07/01/2017 - "Now, 30 years after the cDNA cloning of MR and 60 years of clinical use of steroidal MRAs, novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clinical trials in patients with heart failure, chronic kidney disease (CKD), hypertension and liver disease. " 11/22/2023 - "Non-steroidal MRAs such as esaxerenone, AZD9977, apararenone, ocedurenone (KBP-5074), and finerenone are newly approved or in clinical development for patients with cardiorenal disease including type 2 diabetes (T2D) and chronic kidney disease (CKD), hypertension -/+ CKD or heart failure. "
4.	Chronic Renal Insufficiency 07/01/2017 - "Now, 30 years after the cDNA cloning of MR and 60 years of clinical use of steroidal MRAs, novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clinical trials in patients with heart failure, chronic kidney disease (CKD), hypertension and liver disease. " 11/22/2023 - "Non-steroidal MRAs such as esaxerenone, AZD9977, apararenone, ocedurenone (KBP-5074), and finerenone are newly approved or in clinical development for patients with cardiorenal disease including type 2 diabetes (T2D) and chronic kidney disease (CKD), hypertension -/+ CKD or heart failure. "
5.	Heart Failure 07/01/2017 - "Now, 30 years after the cDNA cloning of MR and 60 years of clinical use of steroidal MRAs, novel non-steroidal MRAs such as apararenone, esaxerenone and finerenone are in late-stage clinical trials in patients with heart failure, chronic kidney disease (CKD), hypertension and liver disease. " 11/22/2023 - "Non-steroidal MRAs such as esaxerenone, AZD9977, apararenone, ocedurenone (KBP-5074), and finerenone are newly approved or in clinical development for patients with cardiorenal disease including type 2 diabetes (T2D) and chronic kidney disease (CKD), hypertension -/+ CKD or heart failure. "

Related Drugs and Biologics

1.	finerenone
2.	esaxerenone
3.	AZD9977
4.	Complementary DNA (cDNA)
5.	Collagen Type IV (Type IV Collagen)
6.	Mineralocorticoid Receptors (Mineralocorticoid Receptor)
7.	Procollagen
8.	Potassium
9.	Peptides (Polypeptides)
10.	Antihypertensive Agents (Antihypertensives)